Pancreatic Cancer Research

ResearcherRutgers, The State University of New JerseyActive in the last 2 years

Salma K. Jabbour

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8200-5371; OpenAlex author ID A5069565044. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 1, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 8

  1. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Revie… Co-author DOI 10.1097/coc.0000000000001076↗
  2. Patterns of Recurrence After Primary Local Therapy for Pancreatic Ductal Adenocarcinoma - A Critical Review of Rationale and Target Delineation for (Neo)Adjuva… Co-author DOI 10.1016/j.prro.2022.06.004↗
  3. Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using cap… Last author DOI 10.21037/jgo-21-503↗
  4. Subcategorizing T1 Staging in Pancreatic Adenocarcinoma Predicts Survival in Patients Undergoing Resection: An Analysis of the National Cancer Database. Co-author DOI 10.1089/pancan.2019.0017↗
  5. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. First author DOI 10.1097/mpa.0000000000000985↗
  6. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Last author DOI 10.21037/apc.2018.07.05↗
  7. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000370↗
  8. A comparison of helical intensity-modulated radiotherapy, intensity-modulated radiotherapy, and 3D-conformal radiation therapy for pancreatic cancer. Last author DOI 10.1016/j.meddos.2010.08.003↗

Trials 1

  1. Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT00878657↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher Leigh Hallemeier · 2 shared papers, 2022–2024 · strength 0.38
  2. Krishan R. Jethwa · 2 shared papers, 2022–2024 · strength 0.38
  3. Shane S. Neibart · 2 shared papers, 2021–2022 · strength 0.31
  4. Rachit Kumar · 2 shared papers, 2017–2024 · strength 0.24
  5. William C. Small · 2 shared papers, 2017–2024 · strength 0.24
  6. Percy P. Lee · 2 shared papers, 2017–2024 · strength 0.24
  7. H. Richard Alexander · 2 shared papers, 2020–2021 · strength 0.21
  8. Mark Joseph Truty · 1 shared paper, 2022 · strength 0.20
  9. Suzanne M. Russo · 1 shared paper, 2024 · strength 0.18
  10. Leila T. Tchelebi · 1 shared paper, 2024 · strength 0.18
  11. Jordan D. Berlin · 1 shared paper, 2024 · strength 0.18
  12. Mihir Maheshkumar Shah · 2 shared papers, 2018–2020 · strength 0.18
  13. Darren R. Carpizo · 2 shared papers, 2018–2020 · strength 0.18
  14. Joseph M. Herman · 2 shared papers, 2017–2018 · strength 0.12
  15. Timothy Michael Pawlik · 2 shared papers, 2017–2018 · strength 0.12
  16. Lyudmyla Derby Berim · 1 shared paper, 2021 · strength 0.11
  17. Prateek Gulhati · 1 shared paper, 2021 · strength 0.11
  18. Howard S. Höchster · 1 shared paper, 2021 · strength 0.11
  19. Stephanie H. Greco · 1 shared paper, 2020 · strength 0.10
  20. Mihir M. Shah · 1 shared paper, 2020 · strength 0.10
  21. Nikhil Yegya‐Raman · 1 shared paper, 2018 · strength 0.08
  22. Elizabeth A. Poplin · 1 shared paper, 2018 · strength 0.08
  23. Charles Chia-chuen Hsu · 1 shared paper, 2018 · strength 0.07
  24. Christopher Lee Wolfgang · 1 shared paper, 2018 · strength 0.07
  25. Amol Kumar Narang · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.